María González‐Cao

4.0k total citations
73 papers, 1.6k citations indexed

About

María González‐Cao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, María González‐Cao has authored 73 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in María González‐Cao's work include Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (16 papers) and Lung Cancer Treatments and Mutations (15 papers). María González‐Cao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (16 papers) and Lung Cancer Treatments and Mutations (15 papers). María González‐Cao collaborates with scholars based in Spain, Italy and United States. María González‐Cao's co-authors include Rafael Rosell, Niki Karachaliou, Salvador Martín‐Algarra, Mariacarmela Santarpía, Santiago Viteri, Giuseppe Altavilla, Cristina Teixidó, Miguel Ángel Molina‐Vila, Álvaro González and Iván Márquez‐Rodas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

María González‐Cao

65 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
María González‐Cao Spain 23 1.0k 659 516 441 384 73 1.6k
Tarek Meniawy Australia 26 1.2k 1.2× 639 1.0× 569 1.1× 626 1.4× 455 1.2× 95 2.1k
Maarten Slagter Netherlands 7 1.4k 1.4× 598 0.9× 411 0.8× 373 0.8× 937 2.4× 9 2.0k
Alberto Fusi Germany 21 909 0.9× 599 0.9× 251 0.5× 491 1.1× 362 0.9× 53 1.5k
Wiam Bshara United States 25 746 0.7× 811 1.2× 328 0.6× 402 0.9× 314 0.8× 73 1.7k
Lucia B. Jilaveanu United States 29 1.3k 1.3× 1.0k 1.6× 826 1.6× 234 0.5× 456 1.2× 66 2.3k
Sasha E. Stanton United States 15 1.1k 1.1× 530 0.8× 274 0.5× 398 0.9× 596 1.6× 36 1.7k
Steffen Ormanns Germany 20 1.0k 1.0× 486 0.7× 315 0.6× 434 1.0× 428 1.1× 70 1.6k
Shoichiro Ohtani Japan 19 939 0.9× 371 0.6× 399 0.8× 375 0.9× 177 0.5× 92 1.4k
Christian Rolfo United States 23 777 0.8× 855 1.3× 588 1.1× 758 1.7× 190 0.5× 68 1.8k

Countries citing papers authored by María González‐Cao

Since Specialization
Citations

This map shows the geographic impact of María González‐Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María González‐Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María González‐Cao more than expected).

Fields of papers citing papers by María González‐Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María González‐Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María González‐Cao. The network helps show where María González‐Cao may publish in the future.

Co-authorship network of co-authors of María González‐Cao

This figure shows the co-authorship network connecting the top 25 collaborators of María González‐Cao. A scholar is included among the top collaborators of María González‐Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María González‐Cao. María González‐Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gregorc, Vanesa, María González‐Cao, Stefania Salvagni, et al.. (2024). KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Journal of Clinical Oncology. 42(17_suppl). LBA8511–LBA8511. 14 indexed citations
2.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to melanoma drugs in Spain: a cross-sectional survey. Clinical & Translational Oncology. 26(10). 2572–2583. 3 indexed citations
3.
Neal, Joel W., Armando Santoro, María González‐Cao, et al.. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports. 5(10). 100666–100666. 2 indexed citations
4.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 27(1). 386–391. 1 indexed citations
5.
Casella, Valentina, Paula Cebollada Rica, Jordi Argilaguet, et al.. (2024). Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis. Viruses. 16(5). 799–799. 1 indexed citations
6.
González‐Cao, María, Xueting Cai, Jillian Wilhelmina Paulina Bracht, et al.. (2024). HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. PubMed. Volume 15. 55–67. 3 indexed citations
7.
Le, Xiuning, Anna Eisert, Te‐Chun Hsia, et al.. (2023). Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.. Journal of Clinical Oncology. 41(16_suppl). 9070–9070.
8.
Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2023). A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clinical Cancer Research. 30(1). 74–81. 28 indexed citations
9.
Rosell, R., Jordi Codony‐Servat, Jessica González, et al.. (2023). KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology. 195. 104228–104228. 14 indexed citations
10.
Rosell, Rafael, Mariacarmela Santarpía, Andrés Aguilar, et al.. (2023). Liquid biopsy in detecting early non-small cell lung cancer. SHILAP Revista de lepidopterología. 1. 100001–100001. 1 indexed citations
11.
Rosell, Rafael, Anisha Jain, Jordi Codony‐Servat, et al.. (2023). Biological insights in non-small cell lung cancer. Cancer Biology and Medicine. 20(7). 1–19. 21 indexed citations
12.
Rosell, Rafael & María González‐Cao. (2022). Ablating lung cancer, knowing the tumor better. The Lancet Regional Health - Europe. 22. 100494–100494. 2 indexed citations
13.
Odeny, Thomas, Kathryn Lurain, Julius Strauss, et al.. (2022). Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. Journal for ImmunoTherapy of Cancer. 10(9). e005128–e005128. 7 indexed citations
14.
Kast, Richard E., Alex Alfieri, Hazem Assi, et al.. (2022). MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. Cancers. 14(10). 2563–2563. 9 indexed citations
15.
Tresserra, F., et al.. (2021). Surgical Management of Vulvar Melanoma: A Case Series. Case Reports in Oncology. 14(2). 1144–1151. 2 indexed citations
16.
González‐Cao, María, Javier Martínez‐Picado, Niki Karachaliou, Rafael Rosell, & Andreas Meyerhans. (2018). Cancer immunotherapy of patients with HIV infection. Clinical & Translational Oncology. 21(6). 713–720. 21 indexed citations
17.
González‐Cao, María, Niki Karachaliou, Mariacarmela Santarpía, et al.. (2018). Activation of viral defense signaling in cancer. Therapeutic Advances in Medical Oncology. 10. 3861408145–3861408145. 14 indexed citations
18.
Alegre, Estíbaliz, Leyre Zubiri, José Luis Perez‐Gracia, et al.. (2015). Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clinica Chimica Acta. 454. 28–32. 134 indexed citations
19.
Pilotto, Sara, Miguel Ángel Molina‐Vila, Niki Karachaliou, et al.. (2015). Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.. PubMed. 4(6). 721–7. 30 indexed citations
20.
Calvo, Emiliano, Javier Cortés, María González‐Cao, et al.. (2002). Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer. Oncology. 63(3). 254–265. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tarek Meniawy Breakdown of academic impact, for papers by Maarten Slagter Breakdown of academic impact, for papers by Alberto Fusi Breakdown of academic impact, for papers by Wiam Bshara Breakdown of academic impact, for papers by Lucia B. Jilaveanu Breakdown of academic impact, for papers by Sasha E. Stanton Breakdown of academic impact, for papers by Steffen Ormanns Breakdown of academic impact, for papers by Shoichiro Ohtani Breakdown of academic impact, for papers by Christian Rolfo
Rankless by CCL
2026